Atea Pharmaceuticals (AVIR) EBIT (2020 - 2022)
Historic EBIT for Atea Pharmaceuticals (AVIR) over the last 3 years, with Q4 2022 value amounting to -$39.9 million.
- Atea Pharmaceuticals' EBIT fell 13292.51% to -$39.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was -$130.6 million, marking a year-over-year decrease of 19441.67%. This contributed to the annual value of -$193.0 million for FY2024, which is 1753.63% down from last year.
- Latest data reveals that Atea Pharmaceuticals reported EBIT of -$39.9 million as of Q4 2022, which was down 13292.51% from -$16.3 million recorded in Q3 2022.
- In the past 5 years, Atea Pharmaceuticals' EBIT registered a high of $121.2 million during Q4 2021, and its lowest value of -$42.2 million during Q1 2022.
- Its 3-year average for EBIT is $67363.6, with a median of -$16.3 million in 2022.
- Per our database at Business Quant, Atea Pharmaceuticals' EBIT soared by 48691.82% in 2021 and then crashed by 47176.24% in 2022.
- Over the past 3 years, Atea Pharmaceuticals' EBIT (Quarter) stood at $20.6 million in 2020, then soared by 486.92% to $121.2 million in 2021, then crashed by 132.93% to -$39.9 million in 2022.
- Its EBIT stands at -$39.9 million for Q4 2022, versus -$16.3 million for Q3 2022 and -$32.3 million for Q2 2022.